Esperion Therapeutics, INC 8-K filings

Esperion Therapeutics announced a 54% year-over-year increase in total revenue for 2023, driven by strong product sales and collaboration revenue, and resolved a significant litigation with its European partner.

Esperion Therapeutics has successfully priced a public offering of common stock, expected to generate approximately $90.8 million in net proceeds.

Esperion Therapeutics estimates its cash, cash equivalents, and short-term investments totaled $82 million as of December 29, 2023, pending final financial closing procedures.

Esperion Therapeutics announced its 2024 financial guidance, projecting operating expenses between $225 million and $245 million.